EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analytical choices drive toxicogenomic potency estimates: a systematic evaluation of transcriptomic points of departure

Imke B Bruns iD, Dayna R Schultz, Emmanuel Demuynck, Friedel Dewulf, Ioannis Theologidis, Steven J Kunnen iD, Lukas S Wijaya, Ilias Frydas, Nafsika Papaioannou, Elisavet Renieri, Thanasis Papageorgiou, Dimosthenis Sarigiannis und 6 weitere

Toxicological Sciences · 2026

DOI: 10.1093/toxsci/kfag115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicological Sciences, 2026. Verfasst von Imke B Bruns und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, 2333 CC, the Netherlands. Hauptthemen laut MEDLINE: Toxicogenetics, Transcriptome, Gene Expression Profiling, Cisplatin. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon Europe Partnership for the Assessment of Risks for Chemicals, European Union’s Horizon Europe Partnership for the Assessment of Risks for Chemicals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Omics technologies are increasingly integrated into next-generation risk assessment, yet quantitative toxicogenomics outcomes remain highly dependent on analytical choices, motivating a systematic evaluation of how bioinformatics workflows influence hazard characterization and transcriptomic Points of Departure (tPOD). Here, we applied 5 independent transcriptomics pipelines to a shared dataset of RPTEC/TERT1 kidney cells exposed to cisplatin across multiple concentrations and time points, comparing effects of pre-processing, benchmark concentration modeling, and pathway-based interpretation strategies. Across workflows, substantial variability was observed in gene-level benchmark concentrations (BMCs). This variability was associated with differences in normalization, filtering, and modeling software, although the present design does not isolate the contribution of individual workflow choices. Despite this variability, convergence increased at later time points as transcriptional responses strengthened, with 24 h consistently identified as the most sensitive time point at the gene level. Aggregation of gene-level BMCs into pathway-based metrics reduced variability but did not eliminate it, with pathway definition emerging as a major determinant of tPOD estimates. Notably, distinct pathway resources showed minimal gene overlap, and smaller, biologically coherent gene sets (e.g. co-expression modules and biomarker panels) produced lower and less dispersed BMCs compared with broader pathway annotations. Furthermore, direct modeling of pathway activity scores yielded systematically different tPODs relative to median-based aggregation, with method-dependent conservativeness influenced by pathway coverage and response strength. Overall, our findings demonstrate that both analytical workflow design and pathway selection critically shape toxicogenomic-derived potency estimates, highlighting the need for harmonized, transparent methodologies to enable robust application of transcriptomics in chemical safety assessment and regulatory decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ToxicogeneticsTranscriptomeGene Expression ProfilingCisplatinAnimalsComputational BiologyRisk AssessmentWorkflowCell LineHumansDose-Response Relationship, Drug

Stichwörter der Autor:innen

benchmark concentrationin vitro transcriptomicsnext generation risk assessmenttranscriptomic point of departureworkflow variability

Substanzen

Cisplatin

Autor:innen und Institutionen

  • Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, 2333 CC, the Netherlands.
  • Environmental Engineering Laboratory, Department of Chemical Engineering, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece.
  • HERACLES Research Center on the Exposome and Health, Center for Interdisciplinary Research and Innovation, Balkan Center, Bldg. B, Thessaloniki, 57001, Greece.
  • Scientific Direction of Chemical and Physical Health Risks, Sciensano, Brussels, 1050, Belgium.
  • Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Brussels, 1090, Belgium.
  • Blue Growth Research Lab, Ghent University, Oostende, 8400, Belgium.

ORCID-Profile: Imke B Bruns, Steven J Kunnen, Jana Asselman

Förderung

  • European Union's Horizon Europe Partnership for the Assessment of Risks for Chemicals
  • European Union’s Horizon Europe Partnership for the Assessment of Risks for Chemicals

Zitieren

APA

Bruns, I. B., Schultz, D. R., Demuynck, E., Dewulf, F., Theologidis, I., Kunnen, S. J., Wijaya, L. S., Frydas, I., Papaioannou, N., Renieri, E., Papageorgiou, T., Sarigiannis, D., Machera, K., Mertens, B., Asselman, J., Weiss, C., van de Water, B., & Callegaro, G. (2026). Analytical choices drive toxicogenomic potency estimates: a systematic evaluation of transcriptomic points of departure. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfag115

Vancouver

Bruns IB, Schultz DR, Demuynck E, Dewulf F, Theologidis I, Kunnen SJ, et al. Analytical choices drive toxicogenomic potency estimates: a systematic evaluation of transcriptomic points of departure. Toxicological Sciences. 2026. doi:10.1093/toxsci/kfag115

BibTeX
@article{Bruns2026,
  author = {Bruns, Imke B and Schultz, Dayna R and Demuynck, Emmanuel and Dewulf, Friedel and Theologidis, Ioannis and Kunnen, Steven J and Wijaya, Lukas S and Frydas, Ilias and Papaioannou, Nafsika and Renieri, Elisavet and Papageorgiou, Thanasis and Sarigiannis, Dimosthenis and Machera, Kyriaki and Mertens, Birgit and Asselman, Jana and Weiss, Carsten and van de Water, Bob and Callegaro, Giulia},
  title = {Analytical choices drive toxicogenomic potency estimates: a systematic evaluation of transcriptomic points of departure},
  journal = {Toxicological Sciences},
  year = {2026},
  doi = {10.1093/toxsci/kfag115}
}
Kostenlos starten →